Insight
When a prescription reaches the pharmacy, the question of "covered or not covered" has already been answered. But for your brand’s ideal and approved patients, the question of "can I afford this?" remains unclear until the moment of truth at pickup. Even with insurance coverage in place, out-of-pocket costs can derail therapy starts before they begin.
The data reflects how often this happens: nearly 50% of patients abandon therapy when out-of-pocket costs exceed $125.[0]IQVIA Medicine Spending & Affordability in the U.S., 2020 For biopharma brands, this represents a meaningful vulnerability in commercial strategy. Market access teams secure coverage. Sales teams drive prescribing decisions. But if the cost at the pharmacy counter exceeds what your patient is prepared to pay, the upstream investment yields no therapy start.
This is the approval paradox: insurance coverage doesn't guarantee affordability, and cost barriers at the point of dispense can be the final obstacle between a prescription and a therapy start. The question for biopharma brands facing this challenge isn't whether to provide copay support — it's how to design that support so it reaches insurance-approved patients with cost relief when and where they need it.
CoverMyMeds offers a copay suite built around a single organizing principle: the right affordability tool for the right moment in your patient’s journey. That suite brings together two complementary solutions — an automatic coupon and a copay card program — and the combined power of both gives brands the ability to maximize reach, design smarter programs and foster adherence across the full medication journey.
Each solution serves a clear and valuable purpose. An automatic coupon excels at eliminating passive abandonment, applying savings at the point of dispense without requiring any action from the patient or pharmacist. A copay card program excels at active patient engagement, reaching patients through targeted communications, supporting complex program designs and delivering sustained adherence management when brands need it. Together, they address cost barriers from multiple angles, each configurable to a brand's patient population, therapy economics and market position.
This is what a comprehensive copay strategy looks like in practice: not a forced choice between passive and active affordability, but a coordinated approach that deploys each solution where it performs best.
The strategic value of copay support runs deeper than fill counts. It touches every commercial investment a brand makes before a patient ever reaches the pharmacy counter.
What makes CoverMyMeds' copay suite strategically different is the ecosystem in which it operates — a network of 1 million providers, 350+ integrated EHRs, 50,000+ pharmacies and health plans/PBMs covering 96% of prescription volume, ensuring both tools activate where patients already fill their prescriptions.
Within that ecosystem, both solutions run through owned adjudication and engagement platforms that enable real-time claim visibility, in-house program changes and data-driven optimization that third-party dependencies can't reliably provide. That means brands coordinate all affordability programs through a single relationship rather than across disconnected vendors. Likewise, pharmacies and providers engage through their existing workflows, using the tools they rely on every day rather than disparate external platforms.
This copay suite is also one component of a broader connected access strategy. When a claim is approved but cost remains a barrier, copay support resolves the affordability challenge at the point of dispense. When a claim is rejected and coverage is possible, prior authorization support initiates the path to insurance approval. And when coverage is unlikely, claim conversion keeps the therapy start moving.
The automatic coupon and copay card program are configured and coordinated within the same ecosystem — one that adapts in real time to what happens at the point of dispense. The brand configures the logic, and the system executes the right intervention based on real-time claim data — whether a patient starts on copay support and loses coverage mid-therapy, requiring PA intervention for continuity, or begins with a rejected claim that is converted to paid before transitioning to copay support once coverage is established.
The CoverMyMeds access ecosystem accommodates these variations precisely because the interventions are embedded in the same network — no separate programs to stitch together, no manual coordination across platforms. Behind that ecosystem is a team with more than 20 years of specialized experience in program design, drawing on claim-level data and cross-program insights to help brands build affordability strategies that fit their commercial goals and adapt as market dynamics shift.
For brands looking to reach every eligible patient at the pharmacy counter — not just the ones who remember to enroll — the automatic coupon helps remove enrollment friction and cost barriers that drive therapy abandonment.
CoverMyMeds' automatic coupon program is integrated within 50,000+ pharmacies, applying savings automatically on 100% of eligible commercial claims at the point of dispense. No app to download. No card to present. No enrollment form to complete. The entire process happens behind the scenes — your patient simply sees the reduced price appear at pickup. The benefit finds your patient rather than waiting for them to find the benefit.
This matters most in the moments when patients are least equipped to act. A patient in cost shock at pickup, facing an unexpected out-of-pocket amount, is not in a position to search for a savings program. The automatic coupon removes that barrier before it ever reaches the patient, helping eliminate one of the primary causes of therapy abandonment.[0]IQVIA Medicine Spending & Affordability in the U.S., 2020
The solution is also designed to catch situations that traditional programs may miss. When a patient's claim is rejected and they're identified as a cash card user, denied claim targeting automatically applies the coupon to keep the therapy start moving. Brands control the program design: the benefit amount, targeting criteria by patient segment, quantity dispensed and more — with variable designs allowing for precision across patient populations and unlimited on-demand reporting giving brands the visibility to optimize spend over time.
Built into that program design, patent-pending Government Plan Exclusion logic helps ensure the right patients receive savings while helping protect brands from misuse — automatically blocking copay savings from known government-funded programs.
In a single year, the automatic coupon saved patients $6 billion and helped prevent more than 12.5 million prescription abandonments at the pharmacy.[0]CoverMyMeds data on file; eVoucher patient savings, Jan–Dec 2023; prescriptions not abandoned, Jan–Dec 2024
For brands that need active, ongoing patient engagement — reaching patients through targeted communications and building adherence through personalized outreach — a copay card program delivers a depth of connection that an automatic solution, by design, doesn’t pursue. It also supports complex program structures that go beyond what fully automated solutions are designed to handle.
CoverMyMeds enables precise direct-to-patient targeting and real-time program adjustments without the delays that third-party vendors introduce. Patients can enroll through a branded website, receive communications via their preferred channel and stay connected to the program throughout their therapy journey.
With 400+ program designs supported and daily claim visibility informing every decision, the program is built for complexity. Brands can configure support for free trial offers, geography-specific needs and a range of leakage protections — including accumulator and maximizer mitigation — with unique cardholder IDs and an at-will network that allows claim processing from any participating pharmacy, ensuring broad reach without overspend. For brands managing gross-to-net impact, cardholder-level data and program controls provide the transparency to forecast spend, track benefit utilization and make adjustments as coverage landscapes shift.
This copay support is an active program, not a passive benefit — one that reaches patients with the right message at the right time. With 28 million claims processed annually and $4.3 billion saved for patients in a single year,[0]CoverMyMeds LoyaltyScript data on file, Jan–Dec 2025 CoverMyMeds delivers the scale and program sophistication that complex brand situations require.
The approval paradox has a solution. The brands that find it are the ones that bring the right affordability tools to the right moments in the patient journey.
The full value of CoverMyMeds' copay suite emerges when both solutions are deployed in a coordinated strategy. Three scenarios illustrate how the automatic coupon and copay card program work together to address the coverage gaps that neither handles as effectively alone.
A patient who forgets their copay card doesn't lose their savings at the point of dispense — the automatic coupon applies and the therapy start is preserved. A patient who fills their prescription at a pharmacy outside the automatic coupon network isn't left without support — they can access savings through the copay card program via the brand's enrollment channel. And at a participating pharmacy, a patient can receive the combined benefit of both — accessing maximum savings through the coordinated application of automatic and card-based affordability in the same transaction.
Together, the automatic coupon and copay card program processed more than 69 million claims in a single year[0]CoverMyMeds claims data on file, Jan–Dec 2024 — a scale that reflects the breadth of the network and the range of affordability moments both solutions are designed to address.
For commercially insured patients on rejected claims, a copay card program can also be configured as an additional layer of affordability support — giving brands another way to address cost barriers at the point of rejection when immediate automated intervention isn't the right first response.
These are predictable features of the patient journey, not exceptional scenarios. The brands using both solutions aren't hedging; they're designing for the full range of coverage moments their patients encounter.
The commercial case for copay support is straightforward: reducing abandonment at the pharmacy directly increases therapy starts, which drives downstream value from patient persistence and adherence. But the strategic value runs deeper than fill counts — it touches every commercial investment a brand makes before a patient ever reaches the pharmacy counter.
When brands remove affordability friction at the point of dispense, they protect the investments made upstream — in formulary negotiation, prescriber education and brand awareness. Copay support, automatic and card-based, helps ensure these efforts translate into actual therapy starts rather than abandoned prescriptions.
For launch brands, the timing is particularly important. Early therapy adoption often shapes long-term market position, and affordability friction in the launch window can slow uptake before a brand establishes its prescribing base. The stakes are real — one in four patients leaves the pharmacy without their medication due to cost.[0]CoverMyMeds Patient Survey 2023 For a launch brand, each of those exits is both a lost therapy start and a patient who is harder to re-engage later.
For established brands, the value lies in continuity — maintaining adherence among patients already on therapy as out-of-pocket costs shift with health plan/PBM formulary changes, benefit resets and accumulator adjustments. A copay strategy that adapts to these changes, rather than relying on patients to navigate support on their own, protects the therapy momentum the brand worked to create.
The traditional approach to copay strategy positions affordability support as a program brands offer and patients must find. Proactive affordability design changes that relationship — embedding support into the workflows where patients already are, reaching them through engagement channels at the moments that matter and building program logic that adapts to coverage realities in real time.
As health plan/PBM dynamics grow more complex and patient cost-sharing increases, brands that treat affordability as a core operational capability — designed into strategy from the start, not layered on in response to abandonment data — gain the predictability and control that reactive programs can't reliably deliver.
The approval paradox has a solution. The brands that find it are the ones that bring the right affordability tools to the right moments in the patient journey — and do so within an ecosystem built to make that coordination seamless.
